Zafgen Inc (NASDAQ:ZFGN) has been given a consensus rating of “Buy” by the seven analysts that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $14.44.

Several equities analysts recently issued reports on the stock. Zacks Investment Research raised shares of Zafgen from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a report on Tuesday. ValuEngine lowered shares of Zafgen from a “buy” rating to a “hold” rating in a report on Monday, November 26th. Finally, BidaskClub lowered shares of Zafgen from a “buy” rating to a “hold” rating in a report on Thursday, November 22nd.

Shares of NASDAQ:ZFGN traded down $0.09 during trading on Friday, reaching $5.02. 570,845 shares of the company were exchanged, compared to its average volume of 492,941. The firm has a market cap of $185.83 million, a PE ratio of -2.64 and a beta of -0.35. Zafgen has a 12-month low of $3.57 and a 12-month high of $12.35. The company has a debt-to-equity ratio of 0.16, a quick ratio of 11.78 and a current ratio of 11.78.

Zafgen (NASDAQ:ZFGN) last issued its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.04. Equities research analysts predict that Zafgen will post -1.96 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of the stock. American International Group Inc. increased its holdings in Zafgen by 36.0% during the third quarter. American International Group Inc. now owns 20,222 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 5,351 shares during the period. Granahan Investment Management Inc. MA boosted its stake in Zafgen by 15.8% in the second quarter. Granahan Investment Management Inc. MA now owns 69,647 shares of the biopharmaceutical company’s stock valued at $712,000 after acquiring an additional 9,503 shares in the last quarter. Voya Investment Management LLC acquired a new stake in Zafgen in the second quarter valued at approximately $104,000. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Zafgen in the second quarter valued at approximately $110,000. Finally, Trexquant Investment LP acquired a new stake in Zafgen in the second quarter valued at approximately $117,000. 81.55% of the stock is currently owned by institutional investors.

About Zafgen

Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.

Recommended Story: What is the NASDAQ Stock Market?

Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.